Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27745524 | 0.85 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL8217430 | 0.82 | KMT2A (0.40) | RAB9ANPC1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL28896250 | 0.80 | PTGER4 (0.38) | RAB9ANPC1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL28896378 | 0.78 | ALDH1A1 (0.40) | RAB9AKMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL1536739 | 0.78 | TSHR (0.45) | RAB9AKMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL1536764 | 0.77 | LMNA (0.44) | RAB9ANPC1KMT2ASMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL25312311 | 0.77 | TSHR (0.44) | RAB9AKMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL21530644 | 0.76 | TSHR (0.46) | RAB9ANPC1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2382998 | 0.76 | KDM4E (0.47) | KMT2ASMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL28896253 | 0.75 | NUDT1 (0.38) | RAB9AKMT2ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
| US-20090124640-A1 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124640-A1 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-2029603-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE AS MYELOPEROXIDASE INHIBITOR | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007142577-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE AS MYELOPEROXIDASE INHIBITOR | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124640-A1 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor | MPO, CAT, GPX1 | RAB9A 2252/4885NPC1 2502/4885KMT2A 2251/4885 |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | RAB9A 2570/4885NPC1 660/4885KMT2A 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.